期刊文献+

A Clinical Study of Garlicin in Treating Acute Cerebral Infarction

A Clinical Study of Garlicin in Treating Acute Cerebral Infarction
全文增补中
导出
摘要 Objective: To evaluate the effect of garlicin in treating acute cerebral infarction.Methods: One hundred and one patients of acute cerebral infarction diagnosed by CT were treated with garlicin (garlicin group) and compared with another group of 53 patients treated with ligustrazine (control group). The neurologic deficiency score and neurologic function score were used for evaluation of effect.Results: The effective rates of garlicin and ligustrazine were 89. 36% and 84. 85% respectively. The improvement scores of neurologic function were 18.46±10.69 and 11.94 ± 6.79 respectively. The difference between the two groups was significant. Before treatment the serum level of MDA in the garlicin group was 6.015 ±1.26 nmol/ml, and it decreased to 4. 87 ± 1.16 nmol/ml after treatment, the change being more significant than that of the control group (from 6.02 ±0.73 nmol/ml to 6.47 ±1.04 nmol/ml). The rheological parameters and cerebral blood flow were also improved after garlicin treatment.Conclusion: Garlicin could increase the perfusion flow of brain, improve the microcirculation, and scavenge free radicals so as to relieve the ischemia and reperfusion injury of the brain. Objective: To evaluate the effect of garlicin in treating acute cerebral infarction.Methods: One hundred and one patients of acute cerebral infarction diagnosed by CT were treated with garlicin (garlicin group) and compared with another group of 53 patients treated with ligustrazine (control group). The neurologic deficiency score and neurologic function score were used for evaluation of effect.Results: The effective rates of garlicin and ligustrazine were 89. 36% and 84. 85% respectively. The improvement scores of neurologic function were 18.46±10.69 and 11.94 ± 6.79 respectively. The difference between the two groups was significant. Before treatment the serum level of MDA in the garlicin group was 6.015 ±1.26 nmol/ml, and it decreased to 4. 87 ± 1.16 nmol/ml after treatment, the change being more significant than that of the control group (from 6.02 ±0.73 nmol/ml to 6.47 ±1.04 nmol/ml). The rheological parameters and cerebral blood flow were also improved after garlicin treatment.Conclusion: Garlicin could increase the perfusion flow of brain, improve the microcirculation, and scavenge free radicals so as to relieve the ischemia and reperfusion injury of the brain.
出处 《Chinese Journal of Integrative Medicine》 SCIE CAS 1998年第2期89-94,共0页 中国结合医学杂志(英文版)
关键词 garlicin acute cerebral infarction LIGUSTRAZINE MALONYLDIALDEHYDE HEMORHEOLOGY garlicin acute cerebral infarction ligustrazine malonyldialdehyde hemorheology
  • 相关文献

参考文献6

  • 1姜德波,章军建,韩仲岩,阮旭中.从自由基病理学探讨脑梗塞治疗的新进展[J].国外医学(神经病学.神经外科学分册),1991,18(2):60-63. 被引量:21
  • 2郑采梅 罗尚贤 等.急性脑血管病血浆及脑脊液中脂质过氧化物含量的观察[J].第三军医大学学报,1988,10(6):433-436.
  • 3赵馥,汪无级.动脉硬化性缺血性脑血液循环障碍[J]神经精神疾病杂志,1979(01).
  • 4Gelmers HJ,Gorter K,Weerdt CT.A controlled trial ofNimodipine in acute ischemic stroke. The New England Journal of Medicine . 1988
  • 5Ernest E,Matrai A,Paulsen F.Leukocyte rheology in re-cent stroke. Stroke . 1987
  • 6Mori E,Del Zoppo GJ,ChambersJD,et al.Inhibition ofPolymorphonuclear leukocyte adherence suppresses noreflowafter focal cerebral ischemla in baboons. Stroke . 1992

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部